Sernova

At Sernova, we are putting well-being at the center of diabetes care as we advance our technology as a potential solution for #Type1Diabetes. We hope to ultimately give patients their lives back by freeing them of burdensome insulin injections. Find out the latest on our #T1D program here: https://bit.ly/4fe94eV #WorldDiabetesDay

In recognition of #DiabetesAwarenessMonth, our President & CEO, Jonathan Rigby, connected with PharmaVoice to discuss his journey living with #Type1Diabetes (#T1D) while working to advance our bio-hybrid organ as a treatment solution for the disease. Check out the article to read about Jonathan’s story: https://bit.ly/3AKiU9p

November is #DiabetesAwarenessMonth. Join us as we work to increase awareness of #Type1Diabetes, which is often misdiagnosed or diagnosed late in adults over 30 years old. At Sernova, we’re dedicated to supporting and improving the standard of care for patients and families affected by #T1D.

Last week we announced several exciting executive appointments. ✅ James Parsons, Chief Financial Officer, will lead Sernova's finance team and ensure the company’s financial strength to support expanding objectives. ✅ Marylyn Rigby, Chief Communications Officer, will direct Sernova’s comprehensive communication strategies to enhance marketing initiatives, expand media relationships, and elevate investor and stakeholder engagement. ✅ David Burke, Vice President of Investor Relations, will ensure transparent, timely, and effective dialogue with current and prospective investors, building trust and fostering long-term support for Sernova’s visionary projects. Learn more by reading the press release: https://bit.ly/3YnWumv

I'm excited to share our science and clinical data on the Cell Pouch Bio Simulated Organ for Type 1 Diabetes treatment. Join me on Monday October 7th at 10 a.m. to learn more about our journey towards a functional cure. "Giving Patients Their Lives Back!" Details here: https://lnkd.in/gsmd5Jap #celltherapy #type1diabetes #IPSC #isletcells

Please listen to Ginger's interview with Sernova leadership on the merits of our cell based treatment of T1D...progress is being made!

We’re excited to attend the 2024 JDRF/FRDJ Canada Walk to Cure Diabetes in Hamilton, ON, this Sunday, September 22nd, both as a local sponsor, and as members of the global #t1d family, to help raise money for type 1 diabetes research. We can’t wait to meet all the participants, families and introduce ourselves! 😃 The Hamilton JDRF crew has a very exciting day planned in addition to the walk, with all sorts of engaging activities, and fun things to do. If you’re in the area, come out and join us on the walk! If you’d like to donate to our team: Sernova’s Superhero’s, the link is below.👇❤️ DONATE: https://lnkd.in/eqFzpxDV REGISTER FOR THE WALK: https://lnkd.in/edhVqCsk

We are pleased to announce that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately. Mr. Paterson is currently employed at Colorado State University as Assistant Vice President for Research Translation and Commercialization where he manages strategic industry relationships. In addition, he brings broad biopharma industry knowledge having worked for Impax Laboratories (IPXL: NASDAQ) in both Europe and North America where he provided leadership and Board support to the business development team for ten years until its acquisition by Amneal Pharmaceuticals (AMRX: NASDAQ). Read more from our press release here: https://lnkd.in/eyE2aaVZ

We’re pleased to announce new positive data from our Phase I/II clinical trial evaluating the safety, tolerability, and efficacy of the Sernova Cell Pouch, containing donor islets in people living with type 1 diabetes (T1D). The Lead Investigator for our Phase I//II trial, Piotr Witkowski M.D., Ph.D. stated “This is a major step forward in the development of a contained and retrievable cell therapy for the treatment of T1D. This is the first evidence that I am aware of that demonstrates this level of healthy islet survival and function in an implantable and retrievable system for such a long duration.” Read our full press release here: https://lnkd.in/ezHcv2aP

Today we shared positive interim data from our Phase I/II #ClinicalTrial evaluating our Cell Pouch Transplant System in #Type1Diabetes. Notably, these data show that islets can function and survive within our Cell Pouch for more than 5 years. Learn more about these data and how this milestone further advances our mission of providing a functional cure for #T1D: https://lnkd.in/eZJVjA_z